MedPath

STRIDES PHARMA, INC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$1.4B
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

10

FDA:10

Drug Approvals

Hydrocortisone

Approval Date
Feb 16, 2024
FDA

Amantadine Hydrochloride

Approval Date
Jul 17, 2023
FDA

Amantadine Hydrochloride

Approval Date
Jul 17, 2023
FDA

POTASSIUM CITRATE

Approval Date
May 25, 2023
FDA

Buspirone Hydrochloride

Approval Date
Mar 30, 2023
FDA

Cinacalcet

Approval Date
Jan 23, 2023
FDA

Efavirenz

Approval Date
Jan 23, 2023
FDA

Ibuprofen

Approval Date
Jan 23, 2023
FDA

Butalbital, Acetaminophen and Caffeine

Approval Date
Mar 11, 2021
FDA

Clinical Trials

No trials found

News

Strides Pharma Gains FDA Approval for Generic Fluoxetine 60mg Tablets

Strides Pharma has received FDA approval for its generic Fluoxetine 60mg tablets, expanding its portfolio of this antidepressant drug.

Strides Pharma Receives USFDA Approval for Generic Theophylline Extended-Release Tablets

Strides Pharma's subsidiary secures USFDA approval for generic Theophylline extended-release tablets, used for chronic asthma and lung diseases.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.